Understanding the Landscape of Rheumatology Biosimilars

In this downloadable slideset, Kenneth G. Saag, MD, MSc, reviews the evidence supporting currently FDA-approved biosimilars.
Stanley B. Cohen, MD
Jonathan Kay, MD
Kenneth G. Saag, MD, MSc
Format: Microsoft PowerPoint (.ppt)
File Size: 542 KB
Released: November 15, 2017

Acknowledgements

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

Supported by independent educational grants from
Boehringer Ingelheim Pharmaceuticals, Inc.
Sandoz Inc., a Novartis Division

Related Content

Expert slides from Clinical Care Options (CCO) on optimal management of inflammatory bowel disease (IBD), including ulcerative colitis, Crohn disease

Uma Mahadevan, MD William Sandborn, MD Released: September 22, 2020

Expert commentary on real-world and trial data on treating RA after failing biologic and targeted small-molecule DMARDs, from EULAR 2020 by CCO

Eric M. Ruderman, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: August 27, 2020 Expired: August 26, 2021

Expert commentary on key studies in RA comorbidities from EULAR 2020 as reported by CCO

Paul Emery, MA, MD, FRCP Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: August 24, 2020 Expired: August 23, 2021

EULAR 2020 on SELECT-CHOICE: upadacitinib vs abatacept for active rheumatoid arthritis with prior inadequate response or intolerance to bDMARDs as reported by CCO

Released: August 17, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue